India's Biocon (BSE code: 532523) and Mylan (Nasdaq: MYL) have announced the launch in Australia of Ogivri (trastuzumab), a biosimilar to Roche’s (ROG: SIX) Herceptin (trastuzumab), for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and will be available on the Pharmaceutical Benefits Scheme (PBS), under which the Australian government provides subsidized prescription drugs to its citizens.
Shares of Biocon gained 3.15% to 230.60 rupees, while those of Mylan, which has a greed to a merger into Pfizer’s (NYSE: PFE) generics and biosimilars business, was down 1.57% at $20.00 pre-market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze